<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin J Gastroenterol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin J Gastroenterol</journal-id>
      <journal-title-group>
        <journal-title>Clinical Journal of Gastroenterology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1865-7257</issn>
      <issn pub-type="epub">1865-7265</issn>
      <publisher>
        <publisher-name>Springer Japan</publisher-name>
        <publisher-loc>Tokyo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24523831</article-id>
      <article-id pub-id-type="pmc">3915077</article-id>
      <article-id pub-id-type="publisher-id">448</article-id>
      <article-id pub-id-type="doi">10.1007/s12328-013-0448-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pure red cell aplasia associated with autoimmune hepatitis successfully treated with cyclosporine A</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sato</surname>
            <given-names>Akira</given-names>
          </name>
          <address>
            <phone>+81-45-3661111</phone>
            <fax>+81-45-3661190</fax>
            <email>asato@marianna-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sano</surname>
            <given-names>Fumiaki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishii</surname>
            <given-names>Toshiya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adachi</surname>
            <given-names>Kayo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Negishi</surname>
            <given-names>Ryujirou</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsumoto</surname>
            <given-names>Nobuyuki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okuse</surname>
            <given-names>Chiaki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <aff id="Aff1"><label/>Division of Gastroenterology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, 1197-1 Yasashicho Asahi-ku, Yokohama, 241-0811 Japan </aff>
        <aff id="Aff2"><label/>Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, 1197-1 Yasashicho Asahi-ku, Yokohama, 241-0811 Japan </aff>
        <aff id="Aff3"><label/>Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, 216-8511 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>8</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>7</volume>
      <issue>1</issue>
      <fpage>74</fpage>
      <lpage>78</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2014</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <title>Abstract
</title>
        <p>A 47-year-old female with a 17-year history of autoimmune hepatitis had been treated with prednisolone, azathioprine, and ursodeoxycholic acid. Although her alanine aminotransferase level occasionally showed mild abnormality, the prednisolone dose could not be increased because she had developed cataract during the course of her illness. In May 2012, she developed severe normochromic normocytic anemia without hemorrhage, and azathioprine was discontinued because it was suspected of being the cause. However, anemia recurred frequently even after discontinuation, necessitating repeated blood transfusions. Bone marrow analysis revealed selective erythroblastopenia, thus leading to a diagnosis of pure red cell aplasia. Cyclosporine A was administered, which led to a dramatic recovery from anemia, and stabilized her alanine aminotransferase levels. Furthermore, the prednisolone dose could be gradually tapered. Pure red cell aplasia associated with autoimmune hepatitis is extremely rare. The present case shows that patients with autoimmune hepatitis refractory to the standard treatment regimen and those with concomitant pure red cell aplasia may be treated with cyclosporine A.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Autoimmune hepatitis</kwd>
        <kwd>Pure red cell aplasia</kwd>
        <kwd>Cyclosporine</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Japan 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="intro">
      <title>Introduction</title>
      <p>Pure red cell aplasia (PRCA) is an acquired anemia that may be primary or secondary to a variety of neoplastic, autoimmune, or infectious diseases or to exposure to various drugs; most cases of PRCA are considered to be autoimmune-mediated [<xref ref-type="bibr" rid="CR1">1</xref>]. Autoimmune hepatitis is a chronic liver inflammation that generally affects young-to-middle-aged women, and immune suppressants, particularly corticosteroids, are effective for treatment. Patients with autoimmune hepatitis occasionally have or acquire concomitant autoimmune diseases, but association with PRCA has rarely been reported. We report a case of PRCA complicated with autoimmune hepatitis that was treated with cyclosporine A (CsA) and exhibited favorable outcomes in managing both diseases.</p>
    </sec>
    <sec id="Sec2">
      <title>Case report</title>
      <p>A 30-year-old female with acute hepatitis was referred to our hospital in 1995. She had been asymptomatic until the disease onset. She had no history of significant medical condition, blood transfusion, or daily intake of medicine and did not consume alcohol. Her serum alanine aminotransferase (ALT) level had fluctuated from 300 to 1116&#xA0;IU/L for 3&#xA0;months before admission. On admission, laboratory examinations revealed total bilirubin 2.5&#xA0;mg/dL, aspartate transaminase (AST) 842&#xA0;IU/L, ALT 956&#xA0;IU/L, alkaline phosphatase 153&#xA0;IU/L, &#x3B3;-glutamyl transpeptidase 68&#xA0;IU/L, &#x3B3;-globulin 2.3&#xA0;g/dL, and immunoglobulin G 2,710&#xA0;mg/dL. Hepatitis B virus surface antigen and hepatitis C virus antibody were negative, antinuclear antibody was weakly positive (1:40, homogeneous), anti-smooth muscle antibody was positive (1:320), and anti-mitochondrial antibody was negative. Human leukocyte antigen was positive for DR-4. Histological analysis of the liver revealed marked interface hepatitis with rosette formation in the parenchyma. On the basis of these findings, she was diagnosed with autoimmune hepatitis and started on prednisolone (30&#xA0;mg/day). Her serum ALT level gradually declined. Her prednisolone dose was tapered to 10&#x2013;15&#xA0;mg/day, which was administered with ursodeoxycholic acid (UDCA; 600&#xA0;mg/day) to maintain her ALT level &lt;40&#xA0;IU/L. Since 2002, she had been treated by a doctor at home, and the aforementioned regimen was continued. In 2008, she developed steroid-induced cataract and was referred to our hospital to consult about treatment options for autoimmune hepatitis. At the time of referral, she was 150&#xA0;cm in height and weighed 43.5&#xA0;kg (body mass index 19.3&#xA0;kg/m<sup>2</sup>), and she was being administered 12.5&#xA0;mg/day of prednisolone and 600&#xA0;mg/day of UDCA, and her serum AST and ALT levels were 23 and 34&#xA0;IU/L, respectively. We added azathioprine (100&#xA0;mg/day) to this regimen and gradually tapered the prednisolone dose to 10&#xA0;mg/day; her ALT level was maintained between 22 and 40&#xA0;IU/L with occasional mild flare-ups. In May 2012, she complained shortness of breath and easy fatigability and significant pallor was noted on physical examination. A hemogram revealed hemoglobin 6.4&#xA0;g/dL, mean red cell volume 117.3 fL, reticulocyte count 0.6&#xA0;%, white blood cell count 2,600 cells/&#x3BC;L, and platelet count 207,000 cells/&#x3BC;L. Laboratory serum analyses revealed total protein 6.0&#xA0;g/dL, albumin 3.7&#xA0;g/dL, AST 32&#xA0;IU/L, ALT 42&#xA0;IU/L, lactic acid dehydrogenase 221&#xA0;IU/L, and normal bilirubin and alkaline phosphatase levels. Her serum iron level was 214&#xA0;&#x3BC;g/dL, erythropoietin level was 3,750 mIU (normal 9.1&#x2013;32.8 mIU), and vitamin B12 and folic acid levels were 307&#xA0;pg/mL (normal 233&#x2013;914&#xA0;pg/mL) and 3.3&#xA0;ng/mL (normal 3.6&#x2013;12.9&#xA0;ng/mL), respectively. She showed no symptoms of recent infection, such as fever or myalgia, and gastrointestinal endoscopy showed no evidence of hemorrhagic lesions. She was initially suspected of having azathioprine-induced anemia; therefore, azathioprine was discontinued. A red cell transfusion was performed, which increased her hemoglobin level to 8.3&#xA0;g/dL; however, after 4&#xA0;weeks, her hemoglobin levels decreased to 6.1&#xA0;g/dL (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Another transfusion was performed; however, severe anemia kept recurring and repeat transfusions were required. Her reticulocyte count was consistently low (0.2&#x2013;0.6&#xA0;%) except just after transfusion. In July 2012, bone marrow aspiration was performed, which revealed hypocellular bone marrow with an absence of erythroblasts. Giant proerythroblast was not observed and her serum was negative for immunoglobulin (Ig)M antibody to parvovirus B19, although viral DNA was not examined. Therefore, she was diagnosed with acquired PRCA on the basis of these findings, and CsA was administered on September 2012 at an initial dose of 6&#xA0;mg/kg/day (250&#xA0;mg/day). After 7&#xA0;weeks, her hemoglobin level and reticulocyte count both showed considerable improvement (12.4&#xA0;g/dL and 2.4&#xA0;%, respectively). The CsA dose was gradually reduced and maintained at 1.6&#xA0;mg/kg/day (70&#xA0;mg/day) since April 2013, without relapse of anemia. Her cyclosporine trough blood level has ranged from 69 to 88&#xA0;ng/mL. In October 2012, UDCA was discontinued and the prednisolone dose was tapered to 9&#xA0;mg/day; prednisolone has been maintained at 8&#xA0;mg/day since January 2013. The mild fluctuations in serum AST and ALT levels noted after azathioprine discontinuation ceased after initiating CsA therapy. Her AST and ALT levels have remained &lt;20&#xA0;IU/L for 8&#xA0;months since the initiation of therapy.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Clinical course of the patient in the present study. <italic>Aza</italic> azathioprine, <italic>PSL</italic> prednisolone, <italic>UDCA</italic> ursodeoxycholic acid, <italic>CsA</italic> cyclosporine A, <italic>BW</italic> body weight, <italic>ANA</italic> antinuclear antibody, <italic>ASMA</italic> anti-smooth muscle antibody, <italic>IgG</italic> immunoglobulin G, <italic>ALT</italic> alanine aminotransferase, <italic>Hb</italic> hemoglobin dosage of all medicines is expressed as dose/day</p></caption><graphic xlink:href="12328_2013_448_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>Our patient presented with acute-onset severe anemia with selective erythroblastopenia in the bone marrow. Therefore, she was diagnosed with PRCA. PRCA is a syndrome characterized by severe normochromic normocytic anemia, reticulocytopenia, and a striking erythroblastopenia in the bone marrow. PRCA is classified into congenital and acquired, and the latter is further classified into idiopathic and secondary to various infections, hematological malignancies, collagen vascular diseases, thymoma, and exposure to a variety of drugs and chemicals [<xref ref-type="bibr" rid="CR1">1</xref>]. Acquired PRCA, except when caused by parvovirus B19 infection, is rare; its incidence in Japan is estimated to be 0.3/1.0 million persons/year [<xref ref-type="bibr" rid="CR2">2</xref>]. Azathioprine is known to cause PRCA; because our patient had been receiving azathioprine for 4&#xA0;years, we initially suspected it might be the cause of anemia. However, drug-induced PRCA remits soon after drug discontinuation [<xref ref-type="bibr" rid="CR1">1</xref>], and azathioprine-induced PRCA has been reported only in renal transplant patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] excluding one case [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, we concluded that azathioprine was an unlikely causative agent. In addition, PRCA develops in patients with various autoimmune diseases, and two cases of PRCA associated with autoimmune hepatitis were reported in 1978 and 1986. Fox et al. [<xref ref-type="bibr" rid="CR6">6</xref>] reported a 37-year-old female patient who was treated with cyclophosphamide and splenectomy for anemia, but these interventions showed limited effectiveness for the disease. Therefore, the patient died 2&#xA0;years after onset of PRCA. In contrast, the 54-year-old female patient reported by Trinchet et al. [<xref ref-type="bibr" rid="CR7">7</xref>] recovered from PRCA with 2&#xA0;months of cyclophosphamide therapy. The clinical findings of these 2 cases, including response to corticosteroid for hepatitis, were consistent with autoimmune hepatitis. However, human parvovirus B19 and hepatitis C virus infections may cause PRCA [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], and these associations were not ruled out. Recently, it was reported that 1&#xA0;% of cases with PRCA were associated with autoimmune hepatitis [<xref ref-type="bibr" rid="CR9">9</xref>], but there are no published reports in which these virus associations were excluded.</p>
      <p>The mechanism of selective erythroid hypoplasia in PRCA is poorly understood; however, most cases of chronic PRCA are considered to be mediated by diverse autoimmune mechanisms, such as antibodies or T cell- and NK cell-mediated, as reviewed by Fisch et al. [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, several immunosuppressive therapies have been used. Of them, CsA, a calcineurin inhibitor, suppresses the immune response by inhibiting the signal transduction pathway [<xref ref-type="bibr" rid="CR11">11</xref>] and exhibits a favorable effect for PRCA [<xref ref-type="bibr" rid="CR9">9</xref>]; it is now recommended as a first-line therapy for the disease [<xref ref-type="bibr" rid="CR12">12</xref>]. On the other hand, the standard treatment for autoimmune hepatitis is corticosteroid with or without azathioprine [<xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR15">15</xref>]. Furthermore, the efficacy of UDCA has been reported in studies from Japan [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], although negative results have also been reported [<xref ref-type="bibr" rid="CR18">18</xref>]. Our patient had been treated with the three aforementioned drugs, but her transaminase levels were not fully controlled. For patients with autoimmune hepatitis refractory to standard therapy, the American Association for the Study of Liver Diseases and the European Association for the Study of Liver evaluated the efficacy of mycophenolate mofetil rather than CsA [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, the British Society of Gastroenterology (BSG) comments that CsA could be used as an alternative therapy in patients who fail to achieve complete biochemical or histological remission on standard therapy considering the balance of its toxicity profile and potential benefits [<xref ref-type="bibr" rid="CR15">15</xref>]. CsA for autoimmune hepatitis was first used by Mistilis et al. [<xref ref-type="bibr" rid="CR19">19</xref>], and subsequent trials confirmed its efficacy in managing autoimmune hepatitis. In one of them, 19 patients (10 with side-effects with or unresponsiveness to corticosteroid) were treated with 2&#x2013;5&#xA0;mg/kg/day (target trough levels 100&#x2013;300&#xA0;ng/mL) of CsA [<xref ref-type="bibr" rid="CR20">20</xref>]. Of them, 15 patients completed 6 months of treatment with significant reductions in serum ALT and histological activity index scores were observed over the 6-month period; moreover, 14 patients achieved complete clinical remission. In another study, 32 children were treated with CsA as a first-line therapy with a starting dose of 4&#xA0;mg/kg/day and adjusted to target trough levels 200&#x2013;300&#xA0;ng/mL in the first 3&#xA0;months followed by 150&#x2013;250&#xA0;ng/mL; within 6&#xA0;months of treatment, 78&#xA0;% patients had normal ALT levels [<xref ref-type="bibr" rid="CR21">21</xref>]. In both studies, clinical findings and laboratory tests including renal functions were monitored weekly or biweekly in the first 2&#xA0;months, followed by monthly monitoring; in addition, there was no significant effect on serum creatinine level, and adverse effect related to CsA appeared mild and transient. Although no trial has evaluated long-term safety of CsA therapy in autoimmune hepatitis, Sciveres et al. [<xref ref-type="bibr" rid="CR22">22</xref>] reported CsA treatment for 8&#x2013;89 (median 35.6) months in 12 patients with autoimmune liver diseases, including 8 patients with autoimmune hepatitis (6 patients with side-effects or unresponsiveness to corticosteroid). The maintenance trough levels of CsA targeted to 100&#x2013;150&#xA0;ng/mL (50&#x2013;100&#xA0;ng/mL after 1&#xA0;year), and complete remission was achieved in all patients without treatment withdrawal due to side-effects. Furthermore, in one Japanese patient, CsA was administered at 100&#xA0;mg/day (1.67&#xA0;mg/kg/day) for &gt;6&#xA0;years without side-effects leading to marked improvement of liver fibrosis&#xA0;[<xref ref-type="bibr" rid="CR23">23</xref>]. Nephropathy is the most common side-effect of CsA; however, multivariate analysis in patients with various autoimmune diseases revealed that administering &lt;5&#xA0;mg/kg/day of CsA and avoidance of increase in serum creatinine of &gt;30&#xA0;% above the patient&#x2019;s baseline value could minimize the development of nephropathy [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, patients with autoimmune hepatitis who are intolerant to corticosteroid or azathioprine, or unresponsive to standard regimen, could be prescribed CsA with careful follow-up.</p>
      <p>In our patient, CsA was administered by chance with the occurrence of PRCA and showed better efficacy than the former therapy of azathioprine plus UDCA, thereby enabling the prednisolone dose to be tapered. The prognosis for patients with PRCA is favorable showing &gt;10&#xA0;years of median survival time [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]; nevertheless, the majority of the patients need maintenance therapy after remission because of frequent relapse due to stopping therapy. Considering that the mean maintenance dose of CsA to prevent relapse is reportedly 2.2&#xA0;mg/kg for idiopathic PRCA [<xref ref-type="bibr" rid="CR9">9</xref>] and 2.5&#xA0;mg/kg for secondary PRCA [<xref ref-type="bibr" rid="CR26">26</xref>], our patient might require continuation of CsA and lower doses of corticosteroid than that administered before PRCA onset to treat autoimmune hepatitis.</p>
      <p>In conclusion, we presented a case of PRCA associated with autoimmune hepatitis, and CsA showed a favorable effect for both diseases. Therefore, CsA should be considered for managing patients with autoimmune hepatitis who are refractory or intolerant to the standard regimen. However, these patients should be monitored for renal toxicity; they may need adequate prevention for infection [<xref ref-type="bibr" rid="CR27">27</xref>] and follow-up for the occurrence of malignancies during long-term CsA therapy.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Disclosures</title>
      <sec id="d30e433">
        <title>Conflict of Interest:</title>
        <p>The authors declare that they have no conflict of interest.</p>
      </sec>
      <sec id="d30e438">
        <title>Ethical Standards:</title>
        <p>This study was approved by the Medical Ethics Committee of St. Marianna University School of Medicine Yokohama City Seibu Hospital. The investigation conforms to the principles outlined in the Declaration of Helsinki.</p>
      </sec>
      <sec id="d30e443">
        <title>Human/Animal Rights:</title>
        <p>All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).</p>
      </sec>
      <sec id="d30e448">
        <title>Informed Consent:</title>
        <p>Informed consent was obtained from the patient for being included in this study.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Dessypris</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Lipton</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Greer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Foerster</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lukens</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Rodgers</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Paraskevas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Glader</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Red cell aplasia</article-title>
          <source>Wintrobe&#x2019;s clinical hematology</source>
          <year>2004</year>
          <edition>11</edition>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
          <fpage>1421</fpage>
          <lpage>1427</lpage>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ozawa</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <collab>Editorial committee of Clinical Guide for Intractable Anemia</collab>
          </person-group>
          <article-title>Reference guide for treatment of pure red cell aplasia (in Japanese)</article-title>
          <source>Clinical guide for intractable anemia</source>
          <year>2011</year>
          <publisher-loc>Tokyo</publisher-loc>
          <publisher-name>Nankodo</publisher-name>
          <fpage>38</fpage>
          <lpage>52</lpage>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrawal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Parrott</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Riad</surname>
              <given-names>HN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Azathioprine-induced pure red cell aplasia: case report and review</article-title>
          <source>Transplant Proc</source>
          <year>2004</year>
          <volume>36</volume>
          <fpage>2689</fpage>
          <lpage>2691</lpage>
          <pub-id pub-id-type="doi">10.1016/j.transproceed.2004.09.047</pub-id>
          <pub-id pub-id-type="pmid">15621125</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koduri</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Vanajakshi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Anuradha</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Azathioprine-associated pure red cell aplasia in renal transplant recipients: a report of two cases</article-title>
          <source>Ann Hematol</source>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nagal</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Azathioprine-induced pure red cell aplasia in a systemic sclerosis patient with interstitial pneumonia</article-title>
          <source>J Dermatol</source>
          <year>2011</year>
          <volume>38</volume>
          <fpage>285</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1346-8138.2010.01005.x</pub-id>
          <pub-id pub-id-type="pmid">21342234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fox</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Firklin</surname>
              <given-names>FC</given-names>
            </name>
          </person-group>
          <article-title>Sequential pure red cell and megakaryocyte aplasia associated with chronic liver disease and ulcerative colitis</article-title>
          <source>Am J Hematol</source>
          <year>1978</year>
          <volume>4</volume>
          <fpage>79</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.2830040110</pub-id>
          <pub-id pub-id-type="pmid">655159</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trinchet</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lacombe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Islam</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of autoimmune chronic active hepatitis and acquired erythroblastopenia cured by cyclophosphamide</article-title>
          <source>Gastroenterol Clin Biol</source>
          <year>1986</year>
          <volume>10</volume>
          <fpage>841</fpage>
          <lpage>844</lpage>
          <pub-id pub-id-type="pmid">3100375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Awani</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sears</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Carrum</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pure red cell aplasia associated with hepatitis C</article-title>
          <source>Am J Med Sci</source>
          <year>1997</year>
          <volume>314</volume>
          <fpage>113</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1097/00000441-199708000-00013</pub-id>
          <pub-id pub-id-type="pmid">9258213</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hirokawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujishima</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA collaborative study group</article-title>
          <source>Haematologica</source>
          <year>2007</year>
          <volume>92</volume>
          <fpage>1021</fpage>
          <lpage>1028</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.11192</pub-id>
          <pub-id pub-id-type="pmid">17640861</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Handgretinger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schaefer</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>Pure red cell aplasia</article-title>
          <source>Br J Haematol</source>
          <year>2000</year>
          <volume>111</volume>
          <fpage>1010</fpage>
          <lpage>1022</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.2000.02429.x</pub-id>
          <pub-id pub-id-type="pmid">11167735</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clipstone</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Timmermann</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The mechanism of action of cyclosporin A and FK506</article-title>
          <source>Clin Immunol Immunopathol</source>
          <year>1996</year>
          <volume>80</volume>
          <fpage>S40</fpage>
          <lpage>S45</lpage>
          <pub-id pub-id-type="doi">10.1006/clin.1996.0140</pub-id>
          <pub-id pub-id-type="pmid">8811062</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujishima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hirokawa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Acquired pure red cell aplasia: updated review of treatment</article-title>
          <source>Br J Haematol</source>
          <year>2008</year>
          <volume>142</volume>
          <fpage>505</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07216.x</pub-id>
          <pub-id pub-id-type="pmid">18510682</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manns</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Czaja</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Gorham</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnosis and management of autoimmune hepatitis</article-title>
          <source>Hepatology</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>2193</fpage>
          <lpage>2213</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.23584</pub-id>
          <pub-id pub-id-type="pmid">20513004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lohse</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Mieli-Vergani</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune hepatitis</article-title>
          <source>J Hepatol</source>
          <year>2011</year>
          <volume>55</volume>
          <fpage>171</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2010.12.012</pub-id>
          <pub-id pub-id-type="pmid">21167232</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gleeson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Heneghan</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>British society of gastroenterology (BSG) guidelines for management of autoimmune hepatitis</article-title>
          <source>Gut</source>
          <year>2011</year>
          <volume>60</volume>
          <fpage>1611</fpage>
          <lpage>1629</lpage>
          <pub-id pub-id-type="doi">10.1136/gut.2010.235259</pub-id>
          <pub-id pub-id-type="pmid">21757447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoneda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yokohama</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>1998</year>
          <volume>13</volume>
          <fpage>490</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1440-1746.1998.tb00674.x</pub-id>
          <pub-id pub-id-type="pmid">9641646</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyake</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Iwasaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kobashi</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis</article-title>
          <source>Hepatol Int</source>
          <year>2009</year>
          <volume>3</volume>
          <fpage>556</fpage>
          <lpage>562</lpage>
          <pub-id pub-id-type="doi">10.1007/s12072-009-9155-9</pub-id>
          <pub-id pub-id-type="pmid">19847577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Czaja</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Lindor</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
          <article-title>Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial</article-title>
          <source>Hepatology</source>
          <year>1999</year>
          <volume>30</volume>
          <fpage>1381</fpage>
          <lpage>1386</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.510300603</pub-id>
          <pub-id pub-id-type="pmid">10573515</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mistilis</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Vickers</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Darroch</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclosporine, a new treatment for autoimmune chronic active hepatitis</article-title>
          <source>Med J Aust</source>
          <year>1985</year>
          <volume>143</volume>
          <fpage>463</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="pmid">4088113</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malekzadeh</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nasseri-Moghaddam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaviani</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis</article-title>
          <source>Dig Dis Sci</source>
          <year>2001</year>
          <volume>46</volume>
          <fpage>1321</fpage>
          <lpage>1327</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1010683817344</pub-id>
          <pub-id pub-id-type="pmid">11414311</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alvarez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ciocca</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ca&#xF1;ero-Velasco</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Short-term cyclosporine induces a remission of autoimmune hepatitis in children</article-title>
          <source>J Hepatol</source>
          <year>1999</year>
          <volume>30</volume>
          <fpage>222</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-8278(99)80065-8</pub-id>
          <pub-id pub-id-type="pmid">10068099</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sciveres</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caprai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Palla</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness and safety of cyclosporine as therapy for autoimmune diseases of the liver in children and adolescents</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>209</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01754.x</pub-id>
          <pub-id pub-id-type="pmid">14723612</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takanashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of autoimmune hepatitis with severe liver fibrosis who was effectively treated with long-term administration of cyclosporine, leading to marked improvement of liver fibrosis (in Japanese)</article-title>
          <source>Kanzo</source>
          <year>2006</year>
          <volume>47</volume>
          <fpage>245</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="doi">10.2957/kanzo.47.245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feutran</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mihatsh</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>For the International kidney biopsy registry of cyclosporine in autoimmune diseases. Risk factors for cyclosporine- induced nephropathy in patients with autoimmune diseases</article-title>
          <source>N Engl J Med</source>
          <year>1992</year>
          <volume>326</volume>
          <fpage>1654</fpage>
          <lpage>1660</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199206183262502</pub-id>
          <pub-id pub-id-type="pmid">1588978</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujishima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sawada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hhirokawa</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA collaborative study group</article-title>
          <source>Haematologica</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>1555</fpage>
          <lpage>1559</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.12871</pub-id>
          <pub-id pub-id-type="pmid">18641028</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hhirokawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sawada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujishima</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term responses and outcomes following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA collaborative study group</article-title>
          <source>Haematologica</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>27</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.11655</pub-id>
          <pub-id pub-id-type="pmid">18166782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Limper</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>Pneumocystis pneumonia</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>2487</fpage>
          <lpage>2498</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra032588</pub-id>
          <pub-id pub-id-type="pmid">15190141</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
